Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) Equity Average (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Equity Average for 6 consecutive years, with $4.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 18.36% year-over-year to $4.5 billion, compared with a TTM value of $4.5 billion through Dec 2025, down 18.36%, and an annual FY2025 reading of $5.4 billion, down 17.72% over the prior year.
  • Equity Average was $4.5 billion for Q4 2025 at Roivant Sciences, down from $4.8 billion in the prior quarter.
  • Across five years, Equity Average topped out at $6.5 billion in Q1 2024 and bottomed at $1.3 billion in Q3 2023.
  • Average Equity Average over 5 years is $3.4 billion, with a median of $2.3 billion recorded in 2021.
  • The sharpest move saw Equity Average crashed 37.09% in 2022, then surged 331.44% in 2024.
  • Year by year, Equity Average stood at $2.3 billion in 2021, then plummeted by 37.09% to $1.5 billion in 2022, then soared by 168.94% to $4.0 billion in 2023, then surged by 40.53% to $5.6 billion in 2024, then decreased by 18.36% to $4.5 billion in 2025.
  • Business Quant data shows Equity Average for ROIV at $4.5 billion in Q4 2025, $4.8 billion in Q3 2025, and $5.0 billion in Q2 2025.